We used additional expression data derived from different breast cancer gene array cohorts, and we tested if the SNAT2 levels correlated with worse outcomes in ER+ patients treated with all adjuvant endocrine treatments (including aromatase inhibitors) or tamoxifen only. The gene discussed is ESR1; the disease is breast cancer.